NCT06447090 VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
| NCT ID | NCT06447090 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Relapse Acute Myeloid Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-04-12 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 30 participants in total. It began in 2024-04-12 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial included 30 cases and aimed to understand the effectiveness and safety of the VMAC regimen combined with donor lymphocyte infusion (DLI) in the treatment of patients with acute myeloid leukemia who have relapsed after allogeneic hematopoietic stem cell transplantation. The main questions it aims to answer are: The safety and efficacy of VMAC combined with DLI in the treatment of allo HSCT recurrence in AML patients;
Eligibility Criteria
Inclusion Criteria: 1. Patients with AML confirmed by bone marrow morphology and morphological recurrence after allo-HSCT (proportion of bone marrow morphological blast cells ≥5%); 2. Age ≥18 years and ≤65 years old, regardless of gender; 3. Eastern Oncology The evaluation of physical status of the cooperative group (ECOG-PS) is 0-2 points; 4. An informed consent form must be signed before the start of the research procedure, and the patient himself or his immediate family members must sign the informed consent form. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the legal guardian or the patient's immediate family member will sign the informed consent form. Exclusion Criteria: Subjects who meet any of the following criteria shall not be enrolled in this study: * 1\) Secondary transplant patients; * 2\) Have a history of tumor and have received any treatment for this tumor in the past 3 years, except for superficial b
Frequently Asked Questions
Who can join the NCT06447090 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Relapse Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06447090 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06447090 currently recruiting?
Yes, NCT06447090 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institute of Hematology & Blood Diseases Hospital, China to inquire about joining.
Where is the NCT06447090 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06447090 clinical trial?
NCT06447090 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.